8,446 Charles River Laboratories International, Inc. $CRL Shares Bought by Ethic Inc.

Ethic Inc. grew its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 271.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 11,559 shares of the medical research company’s stock after acquiring an additional 8,446 shares during the quarter. Ethic Inc.’s holdings in Charles River Laboratories International were worth $3,410,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. North Dakota State Investment Board lifted its position in shares of Charles River Laboratories International by 2.7% during the 3rd quarter. North Dakota State Investment Board now owns 1,489 shares of the medical research company’s stock worth $439,000 after buying an additional 39 shares during the period. Physician Wealth Advisors Inc. boosted its stake in Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after buying an additional 55 shares in the last quarter. Activest Wealth Management grew its position in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 57 shares during the period. Choreo LLC grew its position in Charles River Laboratories International by 2.8% in the third quarter. Choreo LLC now owns 2,165 shares of the medical research company’s stock valued at $639,000 after acquiring an additional 59 shares during the period. Finally, Empirical Finance LLC raised its stake in Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock worth $333,000 after acquiring an additional 62 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 2,156 shares of the stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president owned 4,807 shares in the company, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director owned 1,438 shares of the company’s stock, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 63,352 shares of company stock worth $20,291,281. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $346.29 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The firm has a 50 day moving average of $308.11 and a 200-day moving average of $226.44. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $16.59 billion, a P/E ratio of 380.54, a price-to-earnings-growth ratio of 3.19 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. The business had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. Charles River Laboratories International’s revenue for the quarter was down 2.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.43 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CRL. Jefferies Financial Group lifted their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday, September 28th. Wall Street Zen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Saturday. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Evercore set a $330.00 target price on shares of Charles River Laboratories International in a report on Friday, September 25th. Finally, Morgan Stanley increased their target price on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $308.17.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.